Immobilization of tannery industrial sludge in ceramic membrane preparation and hydrophobic surface modification for application in atrazine remediation from water

2019 ◽  
Vol 39 (10) ◽  
pp. 3235-3246 ◽  
Author(s):  
Debarati Mukherjee ◽  
Susmita Kar ◽  
Arkaprava Mandal ◽  
Sourja Ghosh ◽  
Swachchha Majumdar
Keyword(s):  
Surface Modification ◽  
Ceramic Membrane ◽  
Hydrophobic Surface ◽  
Membrane Preparation ◽  
Industrial Sludge

Hydrophobic surface modification of FMSS and its application as effective sorbents for oil spill clean‐ups and recovery

AIChE Journal ◽  
2017 ◽  
Vol 63 (9) ◽  
pp. 4090-4102 ◽  
Author(s):  
Oluwasola Oribayo ◽  
Qinmin Pan ◽  
Xianshe Feng ◽  
Garry L. Rempel
Keyword(s):  
Surface Modification ◽  
Oil Spill ◽  
Hydrophobic Surface

Hydrophilic/hydrophobic surface modification impact on colloid lithography: Schottky-like defects, dislocation, and ideal distribution

2018 ◽  
Vol 433 ◽  
pp. 443-448 ◽  
Author(s):  
Vasilii Burtsev ◽  
Valentina Marchuk ◽  
Artem Kugaevskiy ◽  
Olga Guselnikova ◽  
Roman Elashnikov ◽  
...  
Keyword(s):  
Surface Modification ◽  
Hydrophobic Surface

Influence of Hydrophobic Surface Modification of Chitosan Based Methotrexate (MTX) Micro Implants to Treat Intraocular Lymphoma

2013 ◽  
Author(s):  
Soumyarwit Manna ◽  
James J. Augsburger ◽  
Zelia M. Correa ◽  
Julio A. Landero ◽  
Rupak K. Banerjee
Keyword(s):  
Surface Modification ◽  
Sustained Release ◽  
Hydrophobic Surface ◽  
Intraocular Lymphoma ◽  
Therapeutic Dosage ◽  
Primary Intraocular Lymphoma ◽  
Rare Form ◽  
Chemotherapeutic Effect ◽  
Oncology Practice ◽  
Micro Implants

Primary intraocular lymphoma (PIOL) is a rare form of lymphoma which is encountered in ocular oncology practice. Most preferred treatment has been intravitreal MTX injections which do not have a long lasting chemotherapeutic effect due to rapid elimination of the drug. In this study, chitosan (CS) and polylactic acid (PLA) based intraocular implants are fabricated for different MTX loadings (10%, 25% and 40% w/w). The implants administer a therapeutic dosage of 0.2–2.0 μg/day of MTX over a period of a month. PLA coated CS-MTX implants can be used for sustained release of MTX, thereby improving the treatment of PIOL.

Sign in / Sign up

Export Citation Format

Share Document